Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Strong 9M operational performance from growth drivers Key growth driver sales 9M 20211 Driving portfolio rejuvenation 51% AimovigⓇ MayzentⓇ KesimptaⓇ 43% Piqray® XiidraⓇ Sales Growth vs. PY Growth vs. PY USD Million USD Million CC Cosentyx (secukinumab) zolgensma 1,009 Entresto sacubitril/valsartan 2,599 3,475 818 41% Key growth drivers and launches 51% of IM sales, growing 25% YTD 589 18% 343 49% PROMACTA 1,498 231 16% (eltrombopag) Kesimpta 225 224 nm (ofatumumab) 33% JAKAVI® 1,187 ruxolitinib 224 18% KISQALI 652 149 27% 26% ribociclib ILARIS 775 (canakinumab) 142 22% Xolair 1,055 139 10% Omalizumab KYMRIAH 444 111 30% (tisagenlecleucel) Tafinlar +Mekinist 1,235 101 6% 9M 2018 9M 2019 9M 2020 MAYZENT. 200 87 74% (siponimod) tablets nm not meaningful 9M 2021 LutatheraⓇ KymriahⓇ KisqaliⓇ llarisⓇ ZolgensmaⓇ Jakavi® Tafinlar+MekinistⓇ PromactaⓇ EntrestoⓇ CosentyxⓇ Other¹ 1. Includes Xolair®, Beovu®, Adakveo®, TabrectaⓇ, Luxturna Ⓡ, Enerzair ®, AtecturaⓇ and LeqvioⓇ 1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 47 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 48 Investor Relations | Q3 2021 Results U NOVARTIS | Reimagining Medicine

View entire presentation